Literature DB >> 16928605

Incidence and etiology of thrombocytosis in an adult Turkish population.

Timucin Aydogan1, Mehmet Kanbay, Ozlem Alici, Ali Kosar.   

Abstract

The aim of the study was to determine the incidence and etiology of thrombocytosis in an adult Turkish population. The medical records of 2000 patients were reviewed retrospectively to determine (i) the etiology of elevated platelet counts, (ii) additional laboratory parameters (i.e., complete blood counts), and (iii) the presence of thromboembolic complications. Within 5 years, 174 678 platelet counts had been performed for 124,340 patients. Of the 124,340 patients, 2000 (1.6%; mean age, 55.2 +/- 17.4 years; range 16-94 years; male-to-female ratio, 3.6:1 [1570:430]) had one or more platelet counts of 500 x 10(3)/mm3 or higher during the study period. Secondary thrombocytosis was the most frequent cause of an elevated platelet count and occurred in 1934 cases (96.7%). Infection was the most common cause of secondary thrombocytosis, occurring in 1001 patients (50.1%). Compared with secondary thrombocytosis, primary thrombocytosis was significantly associated with a higher rate of thromboembolic complications. It is concluded that a high platelet count may have both diagnostic and therapeutic implications. Secondary thrombocytosis is a common finding and mostly secondary to infection. Primary thrombocytosis has a higher risk for thromboembolic events than does secondary thrombocytosis.

Entities:  

Mesh:

Year:  2006        PMID: 16928605     DOI: 10.1080/09537100600746573

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  10 in total

1.  Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma.

Authors:  Ismael Domínguez; Stefano Crippa; Sarah P Thayer; Yin P Hung; Cristina R Ferrone; Andrew L Warshaw; Carlos Fernández-Del Castillo
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

2.  Post electric shock reactive thrombocytosis.

Authors:  Richa Katiyar; Shashikant C U Patne; Pranjal Pankaj
Journal:  J Clin Diagn Res       Date:  2015-04-01

3.  The role of thrombocytapheresis in the management of extreme thrombocytosis: a 6 years' experience from a tertiary care center.

Authors:  Deepika Chenna; Isha Polavarapu; Dhivya Kandasamy; Ganesh Mohan; Shamee Shastry
Journal:  Med Pharm Rep       Date:  2021-10-30

Review 4.  Thrombocytosis in the NICU.

Authors:  David J Powner; W Keith Hoots
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

5.  Marked thrombocytosis during treatment with ceftazidime for pulmonary infection.

Authors:  Huang-Chi Chen; Cheng-Yuan Wang; Chuan-Sheng Wang
Journal:  Pharm World Sci       Date:  2007-07-06

Review 6.  Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.

Authors:  Clemens Stockklausner; C M Duffert; H Cario; R Knöfler; W Streif; A E Kulozik
Journal:  Ann Hematol       Date:  2021-03-12       Impact factor: 3.673

7.  Familial Essential Thrombocythemia With Novel MPL L502G and G208K Mutations.

Authors:  Matthew Rendo; Christian Cavacece; Chung-Ting J Kou; Bradley W Beeler; Joshua Fenderson
Journal:  Cureus       Date:  2022-03-16

8.  Changes in platelet parameters in leukocytosis.

Authors:  Nurinnisa Ozturk; Nurcan Kilic Baygutalp; Ebubekir Bakan; Gulsum Feyza Altas; Harun Polat; Emrullah Dorman
Journal:  Pan Afr Med J       Date:  2016-07-01

9.  Etiology of thrombocytosis in a general medicine population: analysis of 801 cases with emphasis on infectious causes.

Authors:  Stacey R Rose; Nancy J Petersen; Tracie J Gardner; Richard J Hamill; Barbara W Trautner
Journal:  J Clin Med Res       Date:  2012-11-11

10.  Is It Possible to Predict Clonal Thrombocytosis in Triple-Negative Patients with Isolated Thrombocytosis Based Only on Clinical or Blood Findings?

Authors:  Tanja Belčič Mikič; Bor Vratanar; Tadej Pajič; Saša Anžej Doma; Nataša Debeljak; Irena Preložnik Zupan; Matjaž Sever; Samo Zver
Journal:  J Clin Med       Date:  2021-12-11       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.